FIG 4.

Lunit SCOPE IO–powered immune phenotype dictates the responder of immune checkpoint inhibitors especially in PD-L1 tumor proportion score 1%-49%. (A) Forest plot of HR (dot) and 95% CI (arrow) for PFS according to each clinicopathologic subgroup. (B) Proportion of inflamed IP (red), immune-excluded IP (teal), and immune-desert IP (blue) according to PD-L1 TPS. (C) Kaplan-Meier analysis of PFS grouped by PD-L1 TPS status and representative IP in the merged cohort from SMC and SNUBH. (D) ROC curves of Lunit SCOPE IO inflamed score (red) and PD-L1 TPS (blue) to predict immune checkpoint inhibitor responder in PD-L1 TPS 1%-49% subgroup. ALK, anaplastic lymphoma kinase; AUROC, area under the receiver operating characteristic; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ICI, immune checkpoint inhibitors; IP, immune phenotype; mPFS, median progression-free survival; NA, not applicable; ORR, overall response rate; PD-L1, programmed death ligand-1; PFS, progression-free survival; ROC, receiver operating characteristic; SMC, Samsung Medical Center; SNUBH, Seoul National University Bundang Hospital; TPS, tumor proportion score.